Mr. Chris Dallin reports

ASEP MEDICAL ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES AND CORPORATE UPDATE

Further to its news release of April 29, 2026, ASEP Medical Holdings Inc. has closed its private placement on April 30, 2026, and has issued 200 debentures for gross proceeds of $200,000.

The debentures will bear interest at the rate of 12 per cent per annum and will mature on the date that is 12 months from the date of issuance. The company anticipates using the proceeds from the offering for general working capital purposes. Prior to the maturity date, the principal amount of the debentures may be converted, at the option of the holder, into common shares of the company at a conversion price equal to 31 cents per conversion share. The debentures and conversion shares are collectively referred to herein as the securities.

All securities issued in connection with the offering are subject to a statutory hold period expiring four months and one day after the date of issuance of the debentures. The company benefited from a waiver granted by the Canadian Securities Exchange of the five-day advance notice requirement prior to closing.

Further, the company announces that Thomas O'Shaughnessy resigned as a director on April 30, 2026. The company wishes to thank Mr. O'Shaughnessy for his contributions to the company.

About ASEP Medical Holdings Inc.

ASEP Medical is a standout biotechnology research and development company based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E.W. Hancock, one of the world's foremost microbiologists. ASEP holds a controlling interest in two private subsidiary companies: Sepset Biosciences (ASEP's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

We seek Safe Harbor.